Provider P30-16 New Prior Authorization Requirement for Lyme Disease: Diagnostic Testing and Intravenous Antibiotic Therapy Read More
Provider P14-16 Addition of Lazanda ® to Existing Drug-Related Prior Authorization with Quantity Limit Program Read More
Provider P49-16 New Drug-Related Prior Authorization Criteria with Quantity Limit for Zavesca Read More
Provider P24-16 Providers will see a change in our Prior Authorization Process for Government Products Read More
Provider P7-16 Addition of Drugs to the Self-Administered Oral Oncology Prior Authorization with Quantity Limit Program Read More
